德康医疗(DXCM)10月24日收盘后股价大跌15.26%,引发市场广泛关注。公司在发布第三季度超预期业绩后,重申了较为保守的2024年全年销售预期,这引发了投资者对公司未来增长前景的担忧。
德康医疗第三季度实现营收3.45亿美元,同比增长29%,超出华尔街预期。营收增长主要得益于其连续性血糖监测(CGM)设备在糖尿病患者中的强劲需求。但公司同时重申2024年全年销售额预期约为40亿至40.5亿美元。
分析师指出,这一全年预期略显保守,暗示公司增长可能放缓,导致投资者担心公司未来业绩前景。一些投资者担心,公司在销售团队重组、客户流失等问题未完全解决情况下,增长动力或将放缓。种种担忧引发投资者抛售该股,导致其在盘后大幅下跌15.26%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.